Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05384821 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)

Study acronym: MetroWilms
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv6
  2. Study sites: 16 to 18
    • Eligibility criteria expanded, about 4 words
    v5
  3. Site details revised at 5 of 16 sitesv4
  4. Site details revised at 7 of 16 sitesv3
  5. Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
    • Primary completion date: Jan 2027 to May 2028
    • Start date changed from estimate of May 2022 to Sep 14, 2022
    • Study sites: 12 to 16
    • Study completion date: Jan 2028 to Oct 2028
    • Eligibility criteria revised
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multicenter, interventional, non-randomized study among patients with a relapsed or refractory Wilms tumor. The study will aim to assess efficacy of metronomic chemotherapy, in terms of disease control after two cycles of metronomic chemotherapy.
Trial Details
NCT Number NCT05384821
Lead Sponsor Centre Oscar Lambret
Conditions
(from sponsor)		 Wilms Tumor
Related terms Kidney Neoplasms, Wilms Tumor
Enrollment 28 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov